{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:24:11Z","timestamp":1784064251595,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["Study Funding Source"],"award-info":[{"award-number":["Study Funding Source"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s11136-022-03170-7","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T21:12:03Z","timestamp":1657660323000},"page":"1319-1327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-350X","authenticated-orcid":false,"given":"Kathleen W.","family":"Wyrwich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5519-0794","authenticated-orcid":false,"given":"Helen","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-6184","authenticated-orcid":false,"given":"Sarah","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-7431","authenticated-orcid":false,"given":"Natalie V. J.","family":"Aldhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2697-0438","authenticated-orcid":false,"given":"Jake","family":"Macey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2705-7002","authenticated-orcid":false,"given":"Natasha","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4232-5906","authenticated-orcid":false,"given":"Justin M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"Brett A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"issue":"4","key":"3170_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","volume":"75","author":"LY Liu","year":"2016","unstructured":"Liu, L. Y., King, B. A., & Craiglow, B. G. (2016). Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. Journal of the American Academy of Dermatology, 75(4), 806\u201312.e3.","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"3170_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.14497","volume":"175","author":"F Rencz","year":"2016","unstructured":"Rencz, F., Gul\u00e1csi, L., P\u00e9ntek, M., Wikonk\u00e1l, N., Baji, P., & Brodszky, V. (2016). Alopecia areata and health-related quality of life: A systematic review and meta-analysis. British Journal of Dermatology, 175(3), 561\u2013571.","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"3170_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijwd.2017.11.007","volume":"4","author":"DS Davis","year":"2018","unstructured":"Davis, D. S., & Callender, V. D. (2018). Review of quality of life studies in women with alopecia. International Journal of Women\u2019s Dermatology, 4(1), 18\u201322.","journal-title":"International Journal of Women's Dermatology"},{"issue":"3","key":"3170_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/0743558418768248","volume":"34","author":"JJ Wolf","year":"2019","unstructured":"Wolf, J. J., & Hudson, B. P. (2019). Alopecia areata: Factors that impact children and adolescents. Journal of Adolescent Research., 34(3), 282\u2013301.","journal-title":"Journal of Adolescent Research."},{"issue":"6","key":"3170_CR5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/bjd.17463","volume":"180","author":"L Davey","year":"2019","unstructured":"Davey, L., Clarke, V., & Jenkinson, E. (2019). Living with alopecia areata: An online qualitative survey study. British Journal of Dermatology., 180(6), 1377\u20131389.","journal-title":"British Journal of Dermatology."},{"issue":"1","key":"3170_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse, N. V. J., Kitchen, H., Knight, S., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., King, B. A., & Wyrwich, K. W. (2020). \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d A qualitative interview study to understand the psychosocial burden of alopecia areata. Journal of Patient-Reported Outcomes, 4(1), 76.","journal-title":"Journal of Patient-Reported Outcomes"},{"issue":"3","key":"3170_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen, E. A., Hordinsky, M. K., Price, V. H., Roberts, J. L., Shapiro, J., Canfield, D., Duvic, M., King, L. E., Jr., McMichael, A. J., Randall, V. A., Turner, M. L., Sperling, L., Whiting, D. A., Norris, D., National Alopecia Areata Foundation. (2004). Alopecia areata investigational assessment guidelines\u2014Part II. National Alopecia Areata Foundation. Journal of the American Academy of Dermatology, 51(3), 440\u2013447.","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"3170_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jaad.2019.01.022","volume":"81","author":"CG Wambier","year":"2019","unstructured":"Wambier, C. G., & King, B. A. (2019). Rule of thumb: A simple tool to estimate 1% scalp surface area. Journal of the American Academy of Dermatology, 81(2), 630\u2013631.","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"15","key":"3170_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., & Clynes, R. (2016). Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight, 1(15), e89790.","journal-title":"JCI Insight"},{"issue":"15","key":"3170_CR10","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776","volume":"1","author":"M Kennedy Crispin","year":"2016","unstructured":"Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C., Marinkovich, M. P., Christiano, A. M., Oro, A. E., & King, B. A. (2016). Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight, 1(15), e89776.","journal-title":"JCI Insight"},{"key":"3170_CR11","unstructured":"FDA. (2018). Discussion document for the patient-focused drug development public workshop on guidance 3: Select, develop or modify fit-for-purpose clinical outcome assessments. Prepared for a patient-focused drug development guidance public workshop held on October 15\u201316, 2018. https:\/\/www.fda.gov\/media\/116277\/download"},{"issue":"2","key":"3170_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1586\/erp.11.12","volume":"11","author":"LD McLeod","year":"2011","unstructured":"McLeod, L. D., Coon, C. D., Martin, S. A., Fehnel, S. E., & Hays, R. D. (2011). Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Review of Pharmacoeconomics & Outcomes Research, 11(2), 163\u2013169.","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"3","key":"3170_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11136-012-0175-x","volume":"22","author":"KW Wyrwich","year":"2013","unstructured":"Wyrwich, K. W., Norquist, J. M., Lenderking, W. R., & Acaster, S. (2013). Methods for interpreting change over time in patient-reported outcome measures. Quality of Life Research, 22(3), 475\u2013483.","journal-title":"Quality of Life Research"},{"issue":"1","key":"3170_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/2168479015622667","volume":"50","author":"CD Coon","year":"2016","unstructured":"Coon, C. D., & Cappelleri, J. C. (2016). Interpreting change in scores on patient-reported outcome instruments. Ther Innov Regul Sci., 50(1), 22\u201329.","journal-title":"Ther Innov Regul Sci."},{"issue":"4","key":"3170_CR15","first-page":"79","volume":"11","author":"Guidance for industry","year":"2006","unstructured":"Guidance for industry. (2006). patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health and Quality of Life Outcomes, 11(4), 79.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"4","key":"3170_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.clinthera.2016.03.002","volume":"38","author":"HL Gelhorn","year":"2016","unstructured":"Gelhorn, H. L., Kulke, M. H., O\u2019Dorisio, T., Yang, Q. M., Jackson, J., Jackson, S., Boehm, K. A., Law, L., Kostelec, J., Auguste, P., & Lapuerta, P. (2016). Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: A qualitative interview approach. Clinical Therapeutics, 38(4), 759\u2013768.","journal-title":"Clinical Therapeutics"},{"key":"3170_CR17","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1016\/j.nmd.2016.06.366","volume":"26","author":"H Peay","year":"2016","unstructured":"Peay, H., Kennedy, A., Fischer, R., Bronson, A., & Furlong, P. (2016). Promoting meaningful clinical trial outcome measures for Duchenne muscular dystrophy. Neuromuscular Disorders., 26, S187.","journal-title":"Neuromuscular Disorders."},{"issue":"1","key":"3170_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw, S., Qian, Y., Henne, J., Jarecki, J., Hobby, K., & Yeh, W. S. (2017). A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurology, 17(1), 68.","journal-title":"BMC Neurology"},{"issue":"3","key":"3170_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jval.2018.09.2845","volume":"22","author":"R Arbuckle","year":"2019","unstructured":"Arbuckle, R., Staunton, H., Sully, K., Tomkins, S., Khindri, S., Svedsater, H., & Nelsen, L. (2019). Use of both qualitative and quantitative methods to estimate meaningful change thresholds for key endpoints in pediatric asthma trials. Value in Health, 22(3), 340\u2013347.","journal-title":"Value in Health"},{"issue":"1","key":"3170_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12955-020-01579-7","volume":"19","author":"H Kitchen","year":"2021","unstructured":"Kitchen, H., Seitz, C., Trigg, A., Aldhouse, N., Willgoss, T., Schmitz, H., Gater, A., Gerlinger, C., & Haberland, C. (2021). Patients\u2019 and clinicians\u2019 perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). Health and Quality of Life Outcomes, 19(1), 7.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"1","key":"3170_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41687-019-0100-y","volume":"3","author":"H Staunton","year":"2019","unstructured":"Staunton, H., Willgoss, T., Nelsen, L., Burbridge, C., Sully, K., Rofail, D., & Arbuckle, R. (2019). An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. Journal of Patient-Reported Outcomes, 3(1), 16.","journal-title":"Journal of Patient-Reported Outcomes"},{"issue":"2","key":"3170_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology., 3(2), 77\u2013101.","journal-title":"Qualitative Research in Psychology."},{"key":"3170_CR23","volume-title":"Applied thematic analysis","author":"G Guest","year":"2011","unstructured":"Guest, G., MacQueen, K. M., & Namey, E. E. (2011). Applied thematic analysis. Sage."},{"issue":"5","key":"3170_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","volume":"21","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020). Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) Measures for eyebrow, eyelash and nail assessment in alopecia areata. American Journal of Clinical Dermatology, 21(5), 725\u2013732.","journal-title":"American Journal of Clinical Dermatology"},{"key":"3170_CR25","unstructured":"Friese S. ATLAS.ti 7 User Manual Copyright \u00a92014 by ATLAS.ti Scientific Software Development GmbH, Berlin. All rights reserved. Manual Version: 190.20140902. Updated for program version: 7.5 2014 Contract No.: Document Number|."},{"issue":"1","key":"3170_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley, R. G., Feldman, S. R., Nyirady, J., van de Kerkhof, P., & Papavassilis, C. (2015). The 5-point Investigator\u2019s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. The Journal of Dermatological Treatment, 26(1), 23\u201331.","journal-title":"The Journal of Dermatological Treatment"},{"issue":"4","key":"3170_CR27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.18883","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020). The Alopecia Areata Investigator Global Assessment scale: A measure for evaluating clinically meaningful success in clinical trials. British Journal of Dermatology, 183(4), 702\u2013709.","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"3170_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1529-8019.2011.01415.x","volume":"24","author":"EA Olsen","year":"2011","unstructured":"Olsen, E. A. (2011). Investigative guidelines for alopecia areata. Dermatologic Therapy, 24(3), 311\u2013319.","journal-title":"Dermatologic Therapy"},{"issue":"1","key":"3170_CR29","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jisp.2020.05.006","volume":"20","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F., Dutronc, Y., Mesinkovska, N. A., Ko, J. M., & King, B. A. (2020). The role of patients in alopecia areata endpoint development: understanding physical signs and symptoms. The Journal of Investigative Dermatology Symposium Proceedings, 20(1), S71\u2013S77.","journal-title":"The Journal of Investigative Dermatology Symposium Proceedings"},{"issue":"6","key":"3170_CR30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/bjd.19024","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020). Development of the Scalp Hair Assessment PRO\u2122 measure for alopecia areata. British Journal of Dermatology, 183(6), 1065\u20131072.","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"3170_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13555-020-00477-6","volume":"11","author":"J Macey","year":"2021","unstructured":"Macey, J., Kitchen, H., Aldhouse, N. V. J., Burge, R. T., Edson-Heredia, E., McCollam, J. S., Isaka, Y., & Torisu-Itakura, H. (2021). Dermatologist and patient perceptions of treatment success in alopecia areata and evaluation of clinical outcome assessments in Japan. Dermatol Ther (Heidelb),\u00a011(2), 433\u2013447.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"3170_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40900-018-0093-3","volume":"4","author":"M Chalasani","year":"2018","unstructured":"Chalasani, M., Vaidya, P., & Mullin, T. (2018). Enhancing the incorporation of the patient\u2019s voice in drug development and evaluation. Research Involvement and Engagement, 4, 10.","journal-title":"Research Involvement and Engagement"},{"key":"3170_CR33","unstructured":"FDA. (2018). Patient-focused drug development: Collecting comprehensive and representative input. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. https:\/\/www.fda.gov\/media\/139088\/download"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-022-03170-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-022-03170-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-022-03170-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T08:02:04Z","timestamp":1682236924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-022-03170-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["3170"],"URL":"https:\/\/doi.org\/10.1007\/s11136-022-03170-7","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"7 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kathleen W. Wyrwich is a former employee and\u00a0stockholder at Eli Lilly and Company and Pfizer Inc. She is currently employed at\u00a0Bristol Myers Squibb Company.\u00a0Helen Kitchen, Sarah Knight, Natalie V. J. Aldhouse and Jake Macey are employees and stockholders of Clarivate, a health economic and outcomes research consultancy that consults with various pharmaceutical companies. Natasha Mesinkovska has received honoraria\/fees for advisory work with Eli Lilly and Company, Concert Pharmaceuticals Inc, Arena Pharmaceuticals, Nutrafol. Justin M. Ko has served on advisory boards and is a consultant and clinical investigator for Eli Lilly and Company. He has served as a clinical investigator and\/or consultant for AbbVie, Sanofi, Regeneron, Dermira, BMS and Arena Pharmaceuticals. He has received consulting fees from Eli Lilly and Company and Arena Pharmaceuticals. Brett King has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator for Aclaris Therapeutics Inc, Almirall, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences Inc, Eli Lilly and Company, Incyte Corp, Pfizer Inc, TWi Biotechnology Inc, and Viela Bio. He is on speaker bureaus for Eli Lilly, Pfizer Inc, Regeneron and Sanofi Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Western Institutional Review Board [ref #20171820]) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}